United Immunity Revenue

Biotechnology Research • Chuo-Ku, Tokyo, Japan • 11-20 Employees

United Immunity revenue & valuation

Annual revenue	$1,283,325
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$4,200,000
Total funding	$1,200,000

Key Contact at United Immunity

Tadashi Inoue

Vice President

Company overview

Headquarters	1-12-3, Nihonbashi-Muromachi, Chuo-ku, Tokyo, 103-0022, JP
Phone number	+81592315484
Website	unitedimmunity.co.jp
NAICS	541714
Keywords	Biotechnology, Nanotechnology, Cancer, Small Molecules, Infectious Diseases, Vaccines, Fibrosis, Autoimmune Diseases, Mrna, Macrophages, Lipid Nanoparticles, Cold To Hot Tumors, Dentritic Cells, Targeted Myeloid Cells
Founded	2017
Employees	11-20
Socials

United Immunity Email Formats

United Immunity uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@unitedimmunity.co.jp), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@unitedimmunity.co.jp	100%

About United Immunity

United Immunity's mission is to proactively and selectively target myeloid cells to deliver an innovative clinical experience to patients with cancer and infectious diseases. To achieve this, we are developing innovative nanoparticle and lipid nanoparticle (LNP) based on Cholesteryl Pullulan to selectively deliver therapeutic agents to macrophages, dendritic cells, as well as other myeloid cells such as tumor-associated macrophages (TAM), Kupffer cells in the liver, adipose tissue macrophages, and microglia. Our technology can be combined with various payloads including small molecules, mRNA, siRNA, DNA, peptides, proteins, and antibody fragments. United Immunity's Pullulan nanoparticle (PNP) and Pullulan LNP (P-LNP) are ideally suited for cancer and infectious disease vaccines, and have the potential for the treatment of fibrosis, inflammation, autoimmune, and metabolic diseases. Our lead program, UI-102, applies our pullulan nanoparticle to precisely deliver a Toll-like receptor (TLR) agonist to M2-like tumor macrophages in order to modulate the tumor microenvironment from “cold (immune-suppressed)” to “hot (immune-activated)”. UI-102 aims to increase the efficacy of checkpoint inhibitors and other immunotherapy agents while significantly reducing safety risks associated with TLR agonism. We are also using our technology to boost the effectiveness of T-cell therapies and generate in vivo CAR-macrophages.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

Head

Senior

Employees by Department

United Immunity has 3 employees across 3 departments.

Departments

Number of employees

Funding Data

Explore United Immunity's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2024-04-18	12	$1,200,000

Funding Insights

$1,200,000

Total funding amount

$1,200,000

Most recent funding amount

Number of funding rounds

United Immunity Tech Stack

Discover the technologies and tools that power United Immunity's digital infrastructure, from frameworks to analytics platforms.

Google Workspace

Apache HTTP Server

Web servers

PHP

Programming languages

Glide.js

JavaScript libraries

TYPO3 CMS

CMS

core-js

JavaScript libraries

Frequently asked questions

United Immunity is located in Chuo-Ku, Tokyo, JP.

You can reach United Immunity at +81592315484.

United Immunity generates an estimated annual revenue of $1,283,325. This revenue figure reflects the company's market position and business performance in its industry.

United Immunity has an estimated valuation of $4,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

United Immunity was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.

United Immunity has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

United Immunity has raised a total of $1,200,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at United Immunity

Tadashi Inoue

Vice President

4.8

40,000 users